View all the latest information in
acute myeloid leukemia
, arranged by trials and clinical studies. Listed below are recently added trial updates.
Venetoclax plus low-dose cytarabine for AML; results of a phase III trial
Andrew Wei and team recently published their phase III trial results in Blood in which they assessed the safety and efficacy...
VIALE-A study of venetoclax plus azacitidine meets dual primary endpoints
The VIALE-A trial (NCT02993523), comparing venetoclax plus azacitidine to placebo plus azacitidine, has met the dual primary...
FDA grants CC-486 priority review for the treatment of adult patients with AML
On May 1, 2020, the U.S. Food and Drug Administration (FDA) accepted a new drug application (NDA) and granted priority...
Phase III QUAZAR AML-001 trial results
A summary of the QUAZAR AML-001 trial, as presented by Andrew Wei, The Alfred Hospital, Melbourne, AU, at the 61st ASH meeting in Orlando, US.
Summary of TCT 2020 highlights – part 2: Transplant outcomes in patients with adverse risk AML
This article is based on an overview of the International Academy for Clinical Hematology webinar...
Should quizartinib maintenance be SOC after SCT for patients with FLT3 mutated AML?
During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal were delighted to...
Summary of TCT 2020 highlights – part 1: Conditioning regimens for AML and MDS
This article is based on an overview of the International Academy for Clinical Hematology webinar delivered by Bipin...
AML World Awareness Day 2020 | Clinical trials involving novel agents in AML
On April 21, 2020, communities will unite on Acute Myeloid Leukemia (AML) World Awareness Day (WAD) to raise awareness of...